Literature DB >> 24356633

Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.

J H M Merks1, G L De Salvo, C Bergeron, G Bisogno, A De Paoli, A Ferrari, A Rey, O Oberlin, M C G Stevens, A Kelsey, J Michalski, D S Hawkins, J R Anderson.   

Abstract

BACKGROUND: Parameningeal (PM) site is a well-known adverse prognostic factor in children with localized rhabdomyosarcoma (RMS). To identify risk factors associated with outcome at this site, we pooled data from 1105 patients treated in 10 studies conducted by European and North American cooperative groups between 1984 and 2004. PATIENTS AND METHODS: Clinical factors including age, histology, size, invasiveness, nodal involvement, Intergroup Rhabdomyosarcoma Study (IRS) clinical group, site, risk factors for meningeal involvement (MI), study group, and application of radiotherapy (RT) were studied for their impact on event-free and overall survival (EFS and OS).
RESULTS: Ten-year EFS and OS were 62.6 and 66.1% for the whole group. Patients without initial RT showed worse survival (10-year OS 40.8% versus 68.5% for RT treated patients). Multivariate analysis focusing on 862 patients who received RT as part of their initial treatment revealed four unfavorable prognostic factors: age <3 or >10 years, signs of MI, unfavorable site, and tumor size. Utilizing these prognostic factors, patients could be classified into different risk groups with 10-year OS ranging between 51.1 and 80.9%.
CONCLUSIONS: While, in general, PM localization is regarded as an adverse prognostic factor, the current analysis differentiates those with good prognosis (36% patients with 0-1 risk factor: 10-year OS 80.9%) from high-risk PM patients (28% with 3-4 factors: 10-year OS 51.1%). Furthermore, this analysis reinforces the necessity for RT in PM RMS.

Entities:  

Keywords:  meningeal involvement; parameningeal; radiotherapy; rhabdomyosarcoma

Mesh:

Year:  2014        PMID: 24356633      PMCID: PMC3868324          DOI: 10.1093/annonc/mdt426

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  22 in total

1.  Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.

Authors:  Odile Oberlin; Annie Rey; José Sanchez de Toledo; Hélène Martelli; Meriel E M Jenney; Marcelo Scopinaro; Christophe Bergeron; Johannes H M Merks; Nathalie Bouvet; Caroline Ellershaw; Anna Kelsey; David Spooner; Michael C G Stevens
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.

Authors:  D S Hawkins; J R Anderson; C N Paidas; M D Wharam; S J Qualman; A S Pappo; K Scott Baker; W M Crist
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

3.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.

Authors:  W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

4.  Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.

Authors:  S S Donaldson; J Meza; J C Breneman; W M Crist; F Laurie; S J Qualman; M Wharam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-01       Impact factor: 7.038

5.  Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop.

Authors:  O Oberlin; A Rey; J Anderson; M Carli; R B Raney; J Treuner; M C Stevens
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

6.  Parameningeal rhabdomyosarcoma: results of an international workshop.

Authors:  V Benk; C Rodary; S S Donaldson; F Flamant; H Maurer; I Treuner; M Carli; E Gehan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-10-01       Impact factor: 7.038

7.  Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997.

Authors:  Richard Beverly Raney; Jane Meza; James R Anderson; Christopher J Fryer; Sarah S Donaldson; John C Breneman; Thomas J Fitzgerald; Edmund A Gehan; Jeff M Michalski; Jorge A Ortega; Stephen J Qualman; Eric Sandler; Moody D Wharam; Eugene S Wiener; Harold M Maurer; William M Crist
Journal:  Med Pediatr Oncol       Date:  2002-01

8.  A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocol.

Authors:  J Buwalda; P F Schouwenburg; L E C M Blank; J H M Merks; M P Copper; S D Strackee; P A Voûte; H N Caron
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

9.  Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV.

Authors:  Jeff M Michalski; Jane Meza; John C Breneman; Suzanne L Wolden; Fran Laurie; MaryAnn Jodoin; Beverly Raney; Moody D Wharam; Sarah S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

10.  Childhood cancer.

Authors:  R W Miller; J L Young; B Novakovic
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

View more
  16 in total

Review 1.  Rhabdomyosarcoma of the Head and Neck: A Multimodal Approach.

Authors:  Dana L Casey; Suzanne L Wolden
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-18

2.  Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.

Authors:  Matthew M Ladra; Jackie D Szymonifka; Anita Mahajan; Alison M Friedmann; Beow Yong Yeap; Claire P Goebel; Shannon M MacDonald; David R Grosshans; Carlos Rodriguez-Galindo; Karen J Marcus; Nancy J Tarbell; Torunn I Yock
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

3.  Local failure in parameningeal rhabdomyosarcoma correlates with poor response to induction chemotherapy.

Authors:  Matthew M Ladra; Henry C Mandeville; Andrzej Niemierko; Timothy P Padera; Alison M Friedmann; Shannon M MacDonald; David Ebb; Yen-Lin Chen; Nancy J Tarbell; Torunn I Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-08       Impact factor: 7.038

4.  A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study.

Authors:  Matthew M Ladra; Samantha K Edgington; Anita Mahajan; David Grosshans; Jackie Szymonifka; Fazal Khan; Maryam Moteabbed; Alison M Friedmann; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Radiother Oncol       Date:  2014-10-16       Impact factor: 6.280

5.  Clinical characteristics and long-term outcomes of rhabdomyosarcoma in Korean children, adolescents and young adults: a single-center experience.

Authors:  Meerim Park; Jun Ah Lee; Hye Young Jin; Joo-Young Kim; Jong Woong Park; June Hyuk Kim; Hyun Guy Kang; Seog Yun Park; Eun Young Park; Hyeon Jin Park; Byung Kiu Park
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-23       Impact factor: 4.322

6.  Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT).

Authors:  Kirk D Wyatt; Suzi Birz; Douglas S Hawkins; Veronique Minard-Colin; David A Rodeberg; Monika Sparber-Sauer; Gianni Bisogno; Ewa Koscielniak; Gian Luca De Salvo; Martin Ebinger; Johannes H M Merks; Suzanne L Wolden; Wei Xue; Samuel L Volchenboum
Journal:  Pediatr Blood Cancer       Date:  2022-08-15       Impact factor: 3.838

7.  In vivo 3D profiling of site-specific human cancer cell morphotypes in zebrafish.

Authors:  Dagan Segal; Hanieh Mazloom-Farsibaf; Bo-Jui Chang; Philippe Roudot; Divya Rajendran; Stephan Daetwyler; Reto Fiolka; Mikako Warren; James F Amatruda; Gaudenz Danuser
Journal:  J Cell Biol       Date:  2022-09-26       Impact factor: 8.077

8.  Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups.

Authors:  Odile Oberlin; Annie Rey; Kenneth L B Brown; Gianni Bisogno; Ewa Koscielniak; Michael C G Stevens; Douglas S Hawkins; William H Meyer; Trang H La; Modesto Carli; James R Anderson
Journal:  Pediatr Blood Cancer       Date:  2015-08-10       Impact factor: 3.167

9.  A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.

Authors:  Adepitan A Owosho; Shih-Chiang Huang; Sonja Chen; Shruti Kashikar; Cherry L Estilo; Suzanne L Wolden; Leonard H Wexler; Joseph M Huryn; Cristina R Antonescu
Journal:  Oral Oncol       Date:  2016-09-06       Impact factor: 5.337

10.  Excessive Treatment Failures in Patients With Parameningeal Rhabdomyosarcoma With Reduced-dose Cyclophosphamide and Delayed Radiotherapy.

Authors:  John T Lucas; Alberto S Pappo; Jianrong Wu; Daniel J Indelicato; Matthew J Krasin
Journal:  J Pediatr Hematol Oncol       Date:  2018-07       Impact factor: 1.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.